Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.
The pharmacokinetics of ceforanide were evaluated in 11 patients with end stage renal disease (creatinine clearance less than 5 ml/min). A single intravenous dose of 750 mg/m2 produced peak plasma concentrations of 123 +/- 29 microgram/ml. The plasma half-life (T 1/2) of the drug was 19.1 +/- 2.5 h. A 5.5 h hemodialysis session removed 53% of the drug and reduced the T 1/2 to 5 +/- 0.7 h. Plasma concentrations greater than 10 microgram/m2 were maintained without adverse effects with a 1.5-g/m2 dose administered three times a week for 2 weeks.
D000328:Adult; D000368:Aged; D002435:Cefamandole / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000378:metabolism*; D002511:Cephalosporins / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D002511:Cephalosporins; D002435:Cefamandole; C012653:ceforanide